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The prevalence and spread of the current COVID-19 pandemic have highlighted 
the importance of continual improvements upon current microbiological testing methods. 
Rapid and accurate testing can help mitigate spread by improving on the time to 
quarantine and quarantine duration required. As of the writing of this thesis, COVID-19 
has been responsible for more than 500,000 deaths in the United States of America, 
and greater than 2 million deaths globally. The work done in this thesis has shown 
improvements in the current SARS-CoV-2 testing methodology by reducing the time it 
takes for patient testing while maintaining accuracy and the sensitivity required of a 
clinical assay. The protocol developed uses extraction-free RT-PCR testing as well as a 
rapid RT-PCR methodology.  The assay can improve speed and maintain its specificity 
using probe-based detection for the SARS-CoV-2 N gene. This research provides a 
template for increasing the speed of testing for SAR-CoV-2 that can be applied to other 
infectious diseases and thereby help reduce the spread of future epidemics and 






Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously 
nCoV-19 or 2019-nCoV, is the causative agent responsible for the current coronavirus 
disease (COVID-19) pandemic that has been unfolding for over a year now5, 9, 55.   As of 
January 17th, 2021, according to the “COVID-19 Dashboard by the Center for Systems 
Science and Engineering (CSSE) at Johns Hopkins University (JHU),” COVID-19 has 
infected over 93 million people globally and has resulted in just over 2 million deaths9.  
In the United States alone, there have been over 23 million cases resulti22ng in nearly 
400,000 deaths9.  SARS-CoV-2 is a coronavirus, so named for the large spike proteins 
that cause the viral shape to resemble a crown.  Coronaviruses are in the family 
Coronaviridae in the suborder Cornidovirinae and infect a range of different animals. 
They have had a history of causing mild to severe respiratory infections in humans. 
There have been two previous zoonotic coronavirus outbreaks prior to this current 
pandemic. In 2002 there was an outbreak of severe acute respiratory syndrome 
coronavirus (SARS-CoV) in China, and in 2012 there was an outbreak of the Middle 
East respiratory syndrome coronavirus (MERS-CoV), both causing fatal respiratory 
infections7, 15.  The basic SARS-CoV-2 structure, components and symptoms caused 




Figure 1. SARS-CoV-2 structure and common symptoms. 1 
 
 SARS-CoV-2 is further classified as a β-coronavirus (one of four genera of 
coronaviruses). β-coronaviruses are enveloped, positive-sense RNA viruses that infect 
mammals.  SARS-CoV-2 shares 50% and 79% sequence homology with MERS-CoV 
and SARS-CoV respectively29.  It has 88% sequence homology to two bat SARS-like 
coronaviruses (bat-SL-CoVZC45 and bat-SL-CoVZXC21)29. The pandemic is believed 
to have originated as a zoonosis from bats in Wuhan, China where it was first 
reported29. SARS-CoV-2 contains six functional open reading frames (ORFs), arranged 
in a 5’ to 3’ 22order that encode for: replicase polyprotein (ORF1a/ORF1b), spike (S) 
glycoprotein, envelope (E), membrane (M), and nucleocapsid (N) proteins; there are 
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also several nonstructural proteins and interspersed putative ORFs15. Of the 
nonstructural proteins, nonstructural protein 1 (Nsp1) has been shown to play a major 
role in SARS-Cov-2 virulence by suppressing host gene expression50. There have been 
several new strains to arise and the COVID-19 pandemic has shown increasing 
heterogeneity15, 17, 29, 36.  The iconic spike protein is provides the mechanism by which 
SARS-CoV-2 invades host cells, via interaction with angiotensin converting enzyme 2 
(ACE2), similar to SARS-CoV8, 15, 54.  The spike protein structure is shown in Figure 2.    
 
 
Figure 2. SARS-CoV-2 Spike protein.2 
 




Upon binding to ACE2, the host transmembrane protease serine 2 (TMPRSS2) 
cleaves the spike protein, activating it14.  After cleavage of the spike protein, SARS-
CoV-2 enters the cell by endocytosis, or by fusion of the viral and host membranes56.  
Once SARS-CoV2 enters the host cell, it releases its positive-sense RNA genome into 
the cytosol, where host ribosomes can directly translate the early viral proteins, which 
are predominantly viral replicative particles41.  Nsp1 plays a role in aiding SARS-CoV-2 
replication by binding the 40s ribosomal subunit similar to Nsp1 of SARS-CoV16, 50.  This 
binding to the ribosome inhibits the translation of host mRNAs but still allows translation 
of viral RNAs16, 50.  The exact mechanism for how viral RNAs are still allowed to be 
translated is still unknown but it is believed that there is an interaction with the 5’ cap of 
the viral RNAs and Nsp1 that allows translation to continue16, 50.  Much of the site 
associated damage and patient symptoms seen in COVID-19 infection can be explained 




Figure 3. ACE2 tissue expression. Visual recreation of data gathered by The Human Protein Atlas project 
for tissue ACE2 expression that can be seen here https://www.proteinatlas.org/ENSG00000130234-
ACE2/tissue.  3 
 
While the viral replicative cycle can cause direct damage to the host, most of the 
severe outcomes that have been observed in COVID-19 patients are due to the host’s 
own immune response and the development of what has been termed the cytokine 
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storm, or cytokine shock syndrome20, 42, 48.  This syndrome is characterized by a drastic 
increase in pro-inflammatory molecules that promotes widespread cell death. 
With the recent advent of the novel mRNA COVID-19 vaccines from Pfizer and 
Moderna, the end of this deadly pandemic is in sight3, 38. However, until those vaccines 
can reach enough people to achieve herd immunity, coupled with the difficulties of 
mRNA vaccine dispersal and the rise of anti-vaccination sentiments among the 
populace, maintaining quick and accurate testing of COVID-19 infections is of 
paramount importance10, 53.  
 
Current methods for testing of infectious diseases 
The two most prevalent methods for diagnostic testing of infectious diseases are 
PCR and enzyme-linked immunosorbent assays (ELISAs).  An overview of these two 
methods can be visualized in Figure 4.  The major differences between the two methods 
are sample type used, ease of use, and the timepoints at which they can determine 
infection.  PCR primarily uses a swab from the infectious site to check for genetic 
material, while ELISAs require a blood sample to be taken to ultimately utilize the serum 
to check for the presence of antibodies or antigens. PCR assays can be technically 
difficult, require a more fastidious process than ELISAs and must often undergo multiple 
steps on different instruments. In the clinical lab setting, ELISAs are a simple method to 
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utilize. After blood samples are collected, they are centrifuged and placed on an 
automated chemistry analyzer and the test can be completely automated. 
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While ELISAs sound like a better assay based on ease of use and reduced 
chance of user error because of automation, they have a severe drawback, the 
timepoints at which they can detect infection.  PCR tests can determine if a patient is 
infected even at early stages, potentially before they begin showing symptoms but are 
already infectious. Patients will continue to test positive only while they have an active 
infection.  This allows for accurate testing of active infections, which helps for monitoring 
disease spread and with the implementation of quarantine procedures.  ELISAs on the 
other hand can only determine the presence of infection at later stages (once the 
immune system has responded and begun to produce antibodies).  Patient samples will 
continue to test positive after an infection has resolved and the patient may no longer be 
actively infected or a source of spread.  Based on these premises, PCR testing is 
usually the gold standard for infectious disease testing, especially in the case of 
epidemics and pandemics.  It is for these reasons that the method utilized in this thesis 
and the method chosen by the CDC for COVID-19 testing is a PCR based assay. An 
overview of the CDC COVID-19 PCR test, with its specific primers and probes can be 





Figure 5. CDC COVID-19 N1-RnaseP probe-based qRT-PCR assay. 5 
 
 
Polymerase Chain Reaction (PCR) 
Polymerase Chain Reaction (PCR) was a method first developed in 1983 by Dr. 
Karry Mullis, and had its first published use in 198525, 44.  In his own words, it is a 
method that “lets you pick the piece of DNA you’re interested in and have as much of it 
as you want”34.  PCR requires a reaction mixture of dNTPs, salts, primers, a DNA 
template, and a thermostable DNA polymerase. It can be broken down into three basic 
steps: (1) denaturation, where double stranded DNA (dsDNA) is heated until it unzips 
into single stranded DNA (ssDNA); (2) annealing , where the temperature is lowered to 
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allow for primers (short flanking DNA molecules) to bind; (3) extension, when DNA 
polymerase extends the 3’ end of each primer along the template strand.  These three 
steps are then repeated to exponentially increase the DNA targeted by the primers 
(Figure 6).  
 
 
Figure 6. Polymerase Chain Reaction - PCR basic steps. 6 
 
The intricacies that come with developing an effective PCR assay revolve around 
the reaction mixture components and the cycling conditions.  The DNA template, primer 
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design, sample source, and many other factors all play a role in assay design.  Different 
DNA templates have different melting points based on length, GC content, and salt 
concentration. An increase in any of those parameters will cause an increase in the 
melting point (increased denaturation temperature), requiring a polymerase that can 
handle this increase in temperature12, 47, 52.  An increase in GC content causes an 
increase in the number of relative hydrogen bonds for a given length of DNA as GC 
bonds contain three hydrogen bonds versus the two of AT bonds47, 52.  Increasing the 
salt concentration shields the antiparallel strands from the negative charge of their 
phosphate groups, allowing for easier formation of hydrogen bonds47, 52.  Parameters 
can be further affected based on primer concentration, primer delivery method, and 
polymerase type and concentration.  An example formula for calculating the melting 
temperature of a double stranded oligonucleotide is: 
𝑇𝑚 =  
∆𝐻 × 1000




The common salt correction used is: 
(0.368)(𝑁 − 1) ln([𝑚𝑜𝑛𝑜+] + 3.795√[𝑓𝑟𝑒𝑒 𝑀𝑔++])  45. 
∆𝐻 and ∆𝑆 are the enthalpy and entropy, respectively, of base stacking adjusted 
helix initiation factors, [A] and [B] are the concentration of each strand of DNA, and 
[𝑚𝑜𝑛𝑜+] is the concentration of monovalent cations45.  
Polymerase Improvements 
The first iteration of PCR was rather inefficient due to the use of the Klenow 
fragment which was thermolabile and required new additions after every thermal cycle25, 
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33, 34.  The Klenow fragment is a large protein subunit that is produced by treatment of 
DNA polymerase I from E. coli with the protease subtilisin 13, 24.  The Klenow fragment 
retains the 3’ to 5’ exonuclease and the 5’ to 3’ DNA polymerase domains and activity 
but loses the 5’ to 3’ exonuclease activity13, 24. The efficient and world changing method 
that we know today was not fully realized until the addition of a thermostable 
polymerase. Therefore, some may say that the story of PCR arguably begins with the 
discovery and isolation of Taq polymerase (a thermostable DNA polymerase isolated 
from Thermus aquaticus) in 19766.  Taq polymerase allowed for the uninterrupted 
thermal cycling conditions crucial to PCR, and, in 1988, when method met materials, 
PCR became a practical and revolutionary technique43.  PCR was further improved 
upon by the development of a truncated Taq polymerase, called Klentaq, that lacks the 
5’ to 3’ exonuclease activity, similar to the Klenow fragment and hence the similar 
naming, in 199327.  The full length Taq polymerase was still labile at temperatures 
above 90 degrees Celsius; however, the truncated form was able to withstand higher 
temperatures, allowing for longer DNA templates/products and DNA templates with 
higher GC contents to be utilized11, 25, 27.  The increased thermal stability seen in 
Klentaq compared to the Klenow fragment is due to its reduced entropic penalty of 
folding28.   Polymerases have been further improved upon by site directed mutagenesis 
and other experimental methods to increase stability, fidelity, efficiency and to tailor 
polymerases for specific uses2, 4, 11.  The performance of these polymerases can be 








The evolution of PCR (Hot start PCR, RT-PCR, qRT-PCR,  extreme PCR) 
 Improvements to PCR have occurred through reaction mixture modifications as 
well as altering and improving upon the method itself. Some of the improvements and 
modifications to methodology include Hot start PCR, RT-PCR, qRT-PCR, and extreme 
PCR.  Hot start PCR utilizes antibodies or aptamers that bind to the polymerase and will 
inhibit its activation until the temperature is raised during the thermal cycling21. This 
allows one to control the precise starting point of the polymerization and inhibits any 
potential early and erroneous amplification that may occur at ambient temperature21.  
RT-PCR, or reverse-transcription PCR, utilizes a reverse transcriptase (RT), an RNA-
dependent DNA-polymerase, to reverse transcribe transcribe RNA to DNA. This allows 
for the detection and amplification of RNA viruses and is also utilized for gene 
expression analyses.  RT-PCR requires an additional reverse transcription step prior to 
the normal cycling conditions. This reverse transcription step allows the RT to reverse 
transcribe the RNA present to DNA before the normal PCR steps can continue.  qRT-
PCR (quantitative real-time PCR) allows for “real-time” monitoring of the PCR process, 
speeds up testing results rapidly, and has become the gold standard for measuring 
cDNA and gDNA levels49. This real-time monitoring is achieved by the addition of 
fluorophores that emit a wavelength of light that a detector can sense as the PCR 
instrument is running. If there is no amplification, then no light is emitted by the 
fluorophores. There are two methods for fluorophore addition that can be utilized in 
qRT-PCR.  One is the use of an intercalating dye, that will only emit light once it 
intercalates into double stranded DNA. Thus, as the amount of double stranded DNA 
increases through PCR, the amount of light produced increase. While extremely useful, 
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this method has a significant drawback in a lack of sensing specificity. Any DNA that is 
amplified, whether the intended target or not, will cause an increase in fluorescence. A 
more specific method is to utilize a probe-based assay where the probe has a 
fluorophore and quencher integrated into the probe itself. This method allows for only 
light to be emitted when there is amplification of the intended target and is the method 
utilized both by the CDC COVID-19 detection assay, and the method developed in this 
thesis.  Figure 7 gives a visual representation of how the fluorescent probe-based qRT-
PCR assay works.   
 
Figure 7. Fluorescent Probe-based Real Time PCR (qRT-PCR). 7 
 
 
7 Figure Created with BioRender.com 
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 Extreme PCR is a method recently developed at the University of Utah that 
drastically increases the speed at which PCR can occur, reducing completion time from 
hours to minutes or even seconds12, 32, 35, and with extreme one-step RT-PCR occurring 
in as little as 2 minutes39. PCR time to completion is inversely related to the reaction 
mixture components concentration, and by increasing those concentrations one can 
significantly reduce the time PCR takes12.  Specifically, by increasing the polymerase 
and primer concentrations at roughly equal proportions such that there is enough 
polymerase to utilize all of the primers and enough primers for each polymerase to 
utilize.  This increase in concentration can occur by reducing the reaction volume and/or 
by increasing the amount of reaction components used.  The other key factor in the 
speed of extreme PCR is its ability to rapidly cycle the temperature conditions. The 
difference in thermal cycling conditions between Extreme PCR and Conventional PCR 
can be observed in Figure 8.  
 




In extreme PCR, samples are placed in glass capillary tubes (the thermal 
conductivity of glass is 5 to 10 times greater than that of plastic at a given thickness, 
allowing for more rapid thermal cycling conditions) that are rapidly oscillated between a 
hot and cold-water bath by a stepper motor.    
 This thesis will explore improvements to current SARS-CoV-2 testing 
methodologies to improve patient sampling to result times. Consequently, providing 
possible improvements to patient clinical outcomes as well as improvements to 
quarantining procedures. This thesis looks at both extraction-free methodologies, 
skipping the nucleic acid extraction step (step 3 in figures 5 and 9), in a rapid PCR 
assay using clinical grade equipment to provide the basis of a ready to implement 
clinical assay for SARS-CoV-2 testing as well as an extraction-based method using 
extreme PCR to elucidate the time gating bottlenecks in current PCR testing 
procedures.   
 
Materials and Methods 
 
Specimen acquirement and storage 
Nasopharyngeal swabs were collected in 1mL of universal transport media 
(UTM; BD). For spiked samples, the indicated amounts of SARS-CoV-2 inactivated 
virus were added to universal UTM and were subsequently processed. Briefly, samples 
were mixed in a 2:1 ratio of sample and 20% Triton-X100, then vigorously vortexed for 3 
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pulses of 5 seconds each. Following vortexing, samples were centrifuged at 20,000g for 
15 seconds to pellet cell debris. 3.0 µL of supernatant was then used for each reaction.  
Positive patient samples were kindly provided by the University of Washington 
clinical virology laboratory. Briefly, samples were provided on dry ice in UTM or  viral 
transport media (VTM). All samples had previously tested positive using either the 
University of Washington SARS-CoV-2 Real-time RT-PCR assay or Panther Aptima 
TMA for SARS-CoV-2. Quantification value (Cq) for the University of Washington 
SARS-CoV-2 Real-time RT-PCR assay and relative luminescence units (RLU) values 
for the Panther Aptima TMA were also provided.  
 
Primers 
The SARS-CoV-2 N1 CDC primer and probes were used for LightCycler-based 
assays, as seen in Figure 5. Primers targeting the N gene were chosen because it is 
vital for viral replication and is not under selective immune pressure, as say the spike 
protein, aiding to its conserved nature.  Primers for extreme PCR require higher 
annealing temperatures than traditional PCR primers and were designed using the 
NCBI PrimerBlast.  Adjusted NCBI PrimerBlast parameters were: optimal annealing 
temperatures were set to 67°C, oligonucleotide concentration to 10,000 nmol/L, optimal 
product melting temperature to 80°C. Primers were then blasted against all virus, 
bacteria and human Reference Sequences using NCBI PrimerBlast to ensure there 




Table 1. SARS-CoV-2 primers 








SARS-CoV-2 viral RNA, SARS-CoV-2 inactivated virus, and SARS-CoV-2 
quantitative synthetic RNA were acquired from BEI Resources and used for spiking 
samples and as positive controls.  
 
Mastermixes 
For extreme RT-PCR, we performed reactions in 5µL volumes containing 50 
mmol/L Tris (pH, 8.3), 3 mmol/L MgCl2, 200 μmol/L of each dNTP (dATP, dCTP, dGTP, 
dTTP), 500 μg/mL nonacetylated BSA (Sigma), 2% (vol/vol) glycerol (Sigma), 10.0 
μmol/L  of each primer, 1U/μL KlenTaq1, 2X LunaScript RT Enzyme Mix (NEB), and 2.5 
μmol/L Syto9 (Life Technologies). Due to the high concentrations of polymerase and 
primers, reactions were prepared on ice to avoid non-specific amplification and primer-
dimer formation.  
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For rapid PCR conducted on the capillary-based LightCycler 1.5 (Roche), Luna 
Probe One-Step RT-qRT-PCR 4x Mix with UDG (NEB) was used. Reactions were 
performed in 10µL volumes containing 5 μmol/L of each forward and reverse primers for 
indicated targets and 250nmol/L of probe for each indicated target.  
 
Melt curve analysis 
HR-1 from Idaho Technologies was used to generate melt curves.  For 
experiments comparing relative productive amounts, LED voltages were kept constant 
when comparing relative product amounts. The data were analyzed with custom-
created software written in LabView and viewed as the derivative of the melting 
curves37. 
 
PCR Thermocycling conditions 
For LightCycler-based assays the parameters used were: RT was set to 55°C for 
the indicated times, annealing/elongation temperatures were set to 63°C, the 
melt/denaturation step was set to 95°C for a 0s hold, and ramp rates were 20°C/s for all 




Figure 9. SARS-CoV-2 testing procedure schematic. 8 
 
The setup for extreme PCR can be visualized in Figure 10. For extreme PCR, a 
hot bath at 100°C and a cool water bath at 60°C were used for thermal cycling 
parameters. The water baths were heated on electric hotplates with temperature 
monitoring using an Omega OMB-DAQ-56 USB data acquisition module and Type-T 
thermocouples (Omega 5SRTC-TT-T-40-36). A stepper motor (stepper online, model 
#23HS41-1804S), driven by a digital stepper drive (stepper online, DM542T) with pulse 
and direction signaling provided by an Arduino Uno R3 (Sparkfun) rotated samples in a 
custom sample holder between each water bath in <0.2s. The stepper motor was 
controlled using a custom LabView program similar to software previously described12. 
A thermocouple (Omega type T precision fine wire thermocouple, 0.003-inch diameter 
with Teflon insulation) centered in a dedicated control tube was used to measure 
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temperature and trigger stepper motion.  Stepper motor motion was triggered at 84°C 
for denaturation and 67°C for annealing/extension to obtain desired temperature cycling 
profiles for 40 cycles. RT was performed for the indicated amount of time in the cool 
bath at 60°C for indicated times immediately prior to thermocycling. All reactions were 
conducted in standard Roche LightCycler capillaries.  
 
Figure 10. Extreme PCR setup 
 
RT optimization 
10 µL reactions were prepared on ice. Samples were incubated in a 55°C water 
bath for indicated amounts of times followed by a 5-minute incubation in boiling water 
for reverse transcriptase inactivation. Samples were quickly placed on ice until 
22 
 
thermocycling. Samples were thermocycled as above with a 10s annealing/extension 
step. For the 0s RT timepoint, samples were added to boiling water without any 
incubation at 55°C.  
 
PCR cycle time optimization 
10 µL reactions were prepared on ice. RT was conducted in a 55°C water bath 
for 10 minutes followed by a 5-minute incubation in boiling water for reverse 
transcriptase inactivation. Samples were quickly placed on ice until thermocycling. 
Samples were thermocycled for indicated times. For the 0s timepoint, the hold time for 







While it has been shown that reverse transcription can be conducted faster than 
manufacturer’s recommend, we wanted to determine the shortest amount of time 
required for efficient RT39. Typical primer concentrations for extreme RT-PCR range 
from 5-20 μmol/L12, 39.  Because of our reduced polymerase concentrations, and slower 
thermocycling conditions, as compared to extreme RT-PCR, we would be unable to 
efficiently use the higher concentration levels; therefore, we used 5 μmol/L primer 
concentrations. We chose to utilize the Luna Warm Start Reverse Transcriptase 
23 
 
because of its aptamer based warm start inhibition, the reversibility of this warm start 
formulation, as well as its increased thermostability. We utilized the CDC N1 SARS-
CoV-2 primer set for a proof of principle.  
Previous studies examining rapid RT primarily utilized isolated RNA39. As we also 
wanted to optimize this assay for extraction free testing, we examined the time 
requirements for RT with pure RNA, RNA spiked into diluent from a NP swab from an 
uninfected control as well as 10 samples for which the patients had tested positive 
(prepared as in methods). After setting up reactions on ice, we incubated the reaction 
tubes at 55°C for indicated amounts of time. Following indicated incubation times, we 
quickly transferred the reaction capillaries to a boiling water bath (100°C) for 5 minutes 
to denature the reverse transcriptase and subsequently transferred the tube to an ice 
water bath. Reactions were then subjected to PCR amplification using a LightCycler 1.5 
with 30s annealing/extension times.  
We saw efficient RT within 30s for both pure RNA as well as RNA spiked into an 
uninfected control (Figs. 11A-C). However, we saw variation between extraction-free 
positive patient samples for the optimal time required for RT (Fig. 11D), on average 
requiring >5 minutes for efficient RT (Figs. 11E-F). Only a small decrease in cycle 
counts were observed with increasing RT concentrations as previously predicted due to 
our lower polymerase concentrations and slower thermocycling conditions (Fig. 11F-G), 
and a negligible difference in cycle count between the 4x and 2x RT concentrations past 





Figure 11. Reverse Transcription Optimization: (A) Varied concentrations of SARS-CoV-2 genomic 
RNA were spiked into water or an uninfected control NP swab diluent and RT was conducted for 
indicated amounts of time followed by PCR. (B) Relative quantification based on the ddCq relative to the 
longest RT time point. (C) Difference in Cq values between the longest time point and indicated time 
points for spiked samples. (D) Positive patient samples had RT conducted for indicated time amounts 
followed by PCR, numbers in each figure corresponds to the patient sample used. (E) Difference in Cq 
values between each time point based on the ddCq relative to the longest RT time point. (F) SARS-CoV-2 
genomic RNA was spiked into UTM media and ran with 1X, 2X, or 4X RT,and reverse transcription was 
performed for the indicated times. (G) Positive SARS-CoV-2 patient samples were ran with the amount of 
RT indicated and reverse transcription was performed for the indicated times. 
 
PCR cycle optimization 
Because previous studies have reported inhibition when using extraction-free 
samples for SARS-CoV-2 RT-PCR, determining an optimal PCR protocol for our 
methods was crucial.  Most commercial RT-PCR assays for SARS-CoV-2 have an 
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annealing/extension time of ≥ 30s per cycle and we wanted to determine the efficacy of 
reduced cycle times. Previous studies show that annealing/extension times of < 0.5s per 
cycle can be performed; however, those studies were performed on purified DNA. To 
determine the efficacy of both methods of detection for qRT-PCR, our study utilized 
probe-based detection for our light cycler method and used intercalating dyes for our 
Extreme PCR method. Purified RNA, or extraction-free positive patient samples, were 
used to test for the optimal time required for our assay. Samples were all reverse 
transcribed for 10 minutes prior to thermocycling.  
A difference of only 1 cycle count was observed for purified RNA when 
comparing a 0s vs 30s annealing/extension step. This suggests that efficient PCR in our 
assay can be done rapidly and far faster than common commercially available RT-PCR 
assays for SARS-CoV-2 (Figs. 12A, C, D). However, extraction-free positive patient 
samples required a 10s annealing/elongation step for efficient PCR (Fig. 12B), which 
still significantly reduces the time it takes for patient sample processing compared to the 
current common annealing and extension time of ≥ 30 seconds. Cumulatively, we saw 
almost no difference in Cq values between samples with 10s vs. 30s 
annealing/elongation (Figs. 12C-D).  
Using a 10s annealing/elongation step, we next examined the efficiency of our 
reaction using pure RNA as well as RNA spiked into diluent from a NP of an uninfected 
control. Both the pure RNA and spiked NP sample were efficient with efficiencies of 
100.3% and 109.9%, respectively (Figs. 12E-F). Additionally, 20/20 reactions with 3 
copies/reaction tested positive in the spiked NP sample suggesting an LOD of 1.5 
copies/mL (Fig. 12G).  We then determined the effects of increasing polymerase and 
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primer concentrations on Cq of patient samples. A decrease to cycle count was only 
observed when increasing the primer concentration to 5µM from 1µM, and no significant 
change between 5uM, 10µM, and 15µM primer concentrations (Fig. 12E). For 
polymerase concentration testing we only saw an approximately 1 to 1.5 cycle count 
change, depending on the patient sample, when increasing the polymerase 
concentration from 1X to 5X (Fig. 12D).  This difference is ultimately negligible and not 
beneficial when considering the increased cost per sample. No significant change in 
cycle count was observed between the 5X and 10X concentrations (Fig. 12D).  Based 
on these results, we concluded that utilizing 5μM primer concentrations (anything 
greater would place us within the extreme PCR patent held by Witter, Farrar, and the 
University of Utah WO2013177429A2), and 1X polymerase concentrations were ideal 






Figure 122. PCR cycle time optimization: (A) Two concentrations of SARS-CoV-2 genomic RNA were 
spiked into water and RT was conducted for 10 minutes followed by PCR with varied 
annealing/elongation cycle times. (B) Difference in Ct values between the longest cycle time and 
indicated annealing/extension times.  (C)Positive patient samples were reverse transcribed for 10 minutes 
followed by PCR for varied annealing/elongation cycle times. (D)  0 U/μL, 0.125 U/μL, and 0.25 U/μL of 
Taq polymerase were added to the samples shown above for the indicated annealing/extension times. (E)  
Patient samples shown were ran with the primer concentrations shown.  (F) Efficiency of dirLC assay 
using SARS-CoV-2 genomic RNA spiked into water. (G) Efficiency of dirLC assay using SARS-CoV-2 
genomic RNA spiked into uninfected control NP swab diluent. (H) LOD assay for dirLC using SARS-CoV-










Direct Light Cycler Validation 
Based on our optimization studies, we adopted an RT-PCR protocol which 
consisted of a 5-minute RT step at 55°C followed by a 10s denaturation step at 95°C. 
This was then followed by 45 cycles of PCR with a 10s annealing/elongation at 63°C 
with a 0s hold time at 95°C, allowing our protocol to have results in under 30 minutes. 
41 positive patient samples, obtained from the University of Washington, were tested 
using this extraction-free testing protocol. Of the 41 University of Washington positive 
patient samples,16 of the 42 samples were originally run on the University of 
Washington SARS-CoV-2 Real-time RT-PCR assay, and the remaining 26 were run on 
Panther Aptima TMA. 40/41 samples tested positive on our platform. For the 15/16 
samples in which we had Cq values from the original testing, a correlation analysis was 
performed and saw a significant correlation, R2 = 0.763 (Fig. 13). No correlation 
between our Cq values and RFU from the 26 samples originally run on the Panther 
Aptima TMA platform was observed (Fig. 13).  This was an expected result as the 
Panther Aptima TMA platform is an endpoint qualitative assay versus the real-time 
quantitative assay of our light cycler protocol.  For the one sample which did not test 
positive with our protocol, the original Cq values on the University of Washington SARS-
CoV-2 Real-time RT-PCR assay platform were 37.1 for one replicate and not detected 





Figure 13. Direct Light Cycler validation: (A) Schematic diagram of the direct LightCycler protocol. (B) 
Correlation analysis between Ct values from dirLC and Ct values obtained originally during testing at the 
University of Washington Clinical Virology Laboratory. (C) Correlation analysis between Ct values from 
dirLC and RLU values from the Panther Aptima TMA assay conducted on the original samples at the 








Extreme RT-PCR for SARS-CoV-2 
While our protocol on the LightCycler allowed for successful detection of SARS-
Cov-2 in < 30 minutes using extraction-free methodologies and clinically available and 
pertinent equipment and reagents, we also wanted to examine and compare the overall 
time for testing using RNA extraction, followed by extreme RT-PCR (Fig. 14A). Because 
extreme RT-PCR utilizes different concentrations, cycling conditions, and is designed to 
amplify shorter products, we needed to design and use a different primer set targeting 
the nucleocapsid gene of SARS-CoV-2 (Table 1). Successful amplification of the 
desired target was measured by high resolution melt curve analysis of the product. 
Using a 30s RT step and ~1.2s PCR cycles, we were able to successfully amplify 
purified SARS-CoV-2 genomic RNA with successful amplification down to 4 
copies/reaction (Fig. 14B). Additionally, we saw successful amplification of SARS-CoV-
2 RNA spiked into NP swab diluent from a healthy, uninfected control (Fig. 14C). 
However, we did not see successful amplification of positive patient samples which is 
not surprising considering the results from Figures 1-2. Overall, the extreme RT-PCR 
followed by high resolution melting required < 3 minutes.  This data suggests that even 
with the extreme speed of extreme RT-PCR the significant chokepoint on time is the 
genomic isolation step. For future assays, the fastest testing methodologies will be 
those that can utilize extraction-free methodologies or new technologies that improve 




Figure 14. Extreme RT-PCR for SARS-CoV-2: (A) Representation of cycling time in extreme PCR 
(black) vs. traditional cycling times (red). (B) Melt curve analysis from extreme RT-PCR was conducted on 
SARS-CoV-2 genomic RNA spiked into water. The height of the melt peak is relative to final product 
concentration. (C) Melt curve analysis post-extreme RT-PCR was conducted on SARS-CoV-2 genomic 







 COVID-19, as of January 17th, 2021, currently ranks 9th on the death toll list for 
global pandemics, with over 2 million deaths and counting.  The best way to mitigate 
spread and death prior to vaccination is with rapid, easy to use, and accurate testing.  
Not only does fast and accurate testing methodology for infectious disease help with the 
prevention of spread but also serves to improve clinical outcomes for infected patients.  
With the recent development and deployment of the Moderna and Pfizer mRNA COVID-
19 vaccines3, 38, there is an end in sight to this devastating pandemic; however, until 
those vaccines are able to can be administered to enough people to reach a level of 
herd immunity, and with the rise of new variants which the vaccines may not confer 
protection against, fast and accurate testing remains of the utmost importance in 
preventing further spread.  The testing outlined in this thesis is also unaffected by the 
rise of the new SARS-CoV-2 variants as the mutations that have occurred are all 
located in the spike protein due to immune selective pressure. The methods utilized in 
this thesis all target the conserved nucleocapsid gene because it is not under immune 
selective pressure and is likely to remain unchanged. Rapid and accurate testing for 
infectious diseases also allows for proper quarantining procedures, minimizing the time 
a patient must wait to determine if quarantining is necessary, and, determines when 
viral shedding has completed and if quarantining is no longer necessary. This aids in 
reducing patient and hospital costs and improves patient and healthcare worker overall 
health and safety.  
 Several novel testing methods have been developed during the COVID-19 
pandemic that have had varying degrees of success or feasibility, but shortages and 
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delayed testing has continued to plague us during this pandemic and the necessity of 
fast and accurate testing has remained absolute1, 18, 19, 23, 30, 31, 46, 51.  We sought to 
determine methods that would allow for faster and accurate testing methods that 
improve upon the currently available RT-PCR methodologies often take greater than 60 
minutes per patient while remaining economically viable to testing facilities.  By skipping 
the genomic isolation step, extraction-free methodologies save on both time and cost, 
with genomic isolation often taking approximately 45 minutes, making total sample to 
result time take hours.  
 Our studies show that extraction-free RT-PCR is a viable clinical diagnostic 
assay that can drastically reduce patient testing even when using patient samples 
shipped across country from the University of Washington.  Some difference was 
observed between the spiked samples and actual patient samples, suggesting some 
potential inhibition either due to patient mucus or immune mediators; however, all 
samples still coincide with clinical assay results.  This further confirms that optimization 
studies require the use of samples from infected patients rather than uninfected spiked 
samples.  We show that extraction-free RT-PCR requires 5 to 10 minutes for efficient 
RT and 10s annealing/extension per cycle for 45 cycles gives accurate and sensitive 
results in under 30 minutes.  Using isolated RNA, RT-PCR can be further shortened to 
an RT of <30s and <60s for PCR.  The use of more robust polymerases that are 
resistant to the source of inhibition may further speed up the reaction time for extraction-
free methodologies.  
 The methods developed in this research provides an insight into the increases in 
speed of PCR diagnostic assays that can be implemented and further built upon for 
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infectious disease testing now and in the future. The use of clinically approved 
instruments (Roche LightCycler) and commercially available RT-PCR reagents with the 
data obtained using the LightCycler protocol allow for immediate clinical translation and 
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